Jeff Yass’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Jeff Yass’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,417	Closed	-$7.08K	–	13536
2023 Q3	$7.08K	Buy	1,417 +976	+221%	+$6.06K	﹤0.01%	11751
2023 Q2	$3.07K	Buy	+441	New	+$3.8K	﹤0.01%	11850
2022 Q4	–	Sell	-560	Closed	-$8K	–	14022
2022 Q3	$8K	Sell	560 -505	-47%	-$14.8K	﹤0.01%	12824
2022 Q2	$43K	Buy	+1,065	New	+$65.9K	﹤0.01%	12061

Other funds holding NEXI

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jeff Yass's NEXI Position: Q4 2023 in Review

Jeff Yass sold out of NexImmune, Inc. Common Stock (NEXI) in Q4 2023, closing a stake of 1,417 shares — an estimated $7.08K sold.

Jeff Yass first reported a position in NEXI in Q2 2022 and held it in 4 quarters. The position peaked at $43K in Q2 2022. 11 funds tracked by Wall St. Rank hold NEXI as of Q4 2023.

Jeff Yass reported no remaining NexImmune, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Jeff Yass sold 1,417 NexImmune, Inc. Common Stock shares in Q4 2023, an estimated $7.08K.
Jeff Yass first reported a position in NexImmune, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Jeff Yass's NexImmune, Inc. Common Stock position peaked at $43K in Q2 2022.
11 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.